AE Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-7,284
Closed -$780K 1681
2021
Q4
$780K Buy
+7,284
New +$762K 0.01% 1049
2020
Q4
Sell
-7,199
Closed -$667K 1365
2020
Q3
$667K Sell
7,199
-1,510
-17% -$116K 0.01% 758
2020
Q2
$679K Buy
+8,709
New +$589K 0.01% 741

Other funds holding BPMC

AE Wealth Management's BPMC Position: Q1 2022 in Review

AE Wealth Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 7,284 shares — an estimated $780K sold.

AE Wealth Management first reported a position in BPMC in Q2 2020 and held it in 3 quarters. The position peaked at $780K in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • AE Wealth Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • AE Wealth Management sold 7,284 Blueprint Medicines shares in Q1 2022, an estimated $780K.
  • AE Wealth Management first reported a position in Blueprint Medicines in Q2 2020 and held it in 3 quarters.
  • AE Wealth Management's Blueprint Medicines position peaked at $780K in Q4 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on AE Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.